Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30523117 | 1.00 | IDO1 (0.42) | IDO1PDPK1MAOAMAOBCA1 | |
| SCHEMBL8445624 | 1.00 | IDO1 (0.42) | IDO1PDPK1MAOAMAOBCA1 | |
| SCHEMBL3973439 | 1.00 | IDO1 (0.42) | IDO1PDPK1MAOAMAOBCA1 | |
| SCHEMBL1148775 | 1.00 | IDO1 (0.42) | IDO1PDPK1MAOAMAOBCA1 | |
| Water SCHEMBL27660893 | 0.98 | IDO1 (0.41) | IDO1PDPK1MAOAMAOBCA1 | |
| SCHEMBL29795931 | 0.89 | IDO1 (0.45) | IDO1 | |
| SCHEMBL1148722 | 0.89 | IDO1 (0.45) | IDO1 | |
| SCHEMBL3318970 | 0.89 | IDO1 (0.45) | IDO1 | |
| SCHEMBL28568250 | 0.82 | ALDH1A1 (0.34) | — | |
| SCHEMBL2541173 | 0.81 | IDO1 (0.42) | IDO1PDPK1MAOAMAOBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116396189-A | Preparation method of (S) - (+) -1-indanyl isocyanate | 无锡科华生物科技有限公司 | 2023-07-07 | — | — | CN | claimed |
| CN-116396189-A | Preparation method of (S) - (+) -1-indanyl isocyanate | 无锡科华生物科技有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116396189-A | Preparation method of (S) - (+) -1-indanyl isocyanate | 无锡科华生物科技有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116396189-A | Preparation method of (S) - (+) -1-indanyl isocyanate | 无锡科华生物科技有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-106232667-B | Polyiso-ureas | 巴斯夫欧洲公司 | 2020-01-07 | — | — | CN | disclosed |
| US-20180298557-A1 | METHODS FOR TREATING PAPERBOARDS AND PAPER MEDIA, AND ASSOCIATED TREATED PAPERBOARDS AND PAPER MEDIA | BASF CORPORATION | 2018-10-18 | — | — | US | disclosed |
| EP-3107946-B1 | A POLYISO-UREA | BASF SE (DE) | 2018-08-08 | — | — | EP | disclosed |
| US-9982083-B2 | Polyiso-urea | BASF SE (DE) | 2018-05-29 | — | — | US | disclosed |
| EP-3298194-A2 | METHODS FOR TREATING PAPERBOARDS AND PAPER MEDIA, AND ASSOCIATED PAPERBOARDS AND PAPER MEDIA | BASF SE (DE) | 2018-03-28 | — | — | EP | disclosed |
| US-20170058074-A1 | POST-MODIFIED POLYCARBODIIMIDES | BASF SE (DE) | 2017-03-02 | — | — | US | disclosed |
| EP-1896485-B1 | AZOLOPYRIDINE-2-ON DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI AVENTIS (FR) | 2010-05-19 | — | — | EP | disclosed |
| US-20100105719-A1 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI-AVENTIS (FR) | 2010-04-29 | — | — | US | disclosed |
| US-20100075961-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-25 | — | — | US | disclosed |
| US-20100075961-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-25 | — | — | US | disclosed |
| CN-101646655-A | Imidazolidine carboxamide derivatives as lipase and phospholipase inhibitors | SANOFI AVENTIS FR | 2010-02-10 | — | — | CN | disclosed |
| EP-2144885-A1 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | Sanofi-Aventis (FR) | 2010-01-20 | — | — | EP | disclosed |
| CN-101415706-A | Azolopyridin-3-one derivatives as inhibitors of endothelial lipase | SANOFI AVENTIS (FR) | 2009-04-22 | — | — | CN | disclosed |
| US-20090054478-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | US | disclosed |
| WO-2008122352-A1 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-16 | — | — | WO | disclosed |
| US-20080167339-A1 | AZOLOPYRIDIN-2-ONE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI-AVENTIS (FR) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075961-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFRKB, NR0B1, NFKB2 | IDO1 1848/4885PDPK1 2646/4885MAOA 3840/4885 |
| US-20080167339-A1 | AZOLOPYRIDIN-2-ONE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | LIPG, LPL, PON1 | IDO1 1196/4885PDPK1 547/4885MAOA 2390/4885 |
| US-20090054478-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | PNLIP, LPL, CEL | IDO1 732/4885PDPK1 260/4885MAOA 400/4885 |
| US-20100105719-A1 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | PNLIP, PLD1, PLD2 | IDO1 408/4885PDPK1 695/4885MAOA 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.